AKRO Company Profile and Key Details
Akero Therapeutics, Inc.
AKRO Stock Price Chart
Stock Price Today
Akero Therapeutics, Inc. (AKRO) stock surged +4.92%, trading at $54.00 on NASDAQ, up from the previous close of $51.47. The stock opened at $52.48, fluctuating between $51.79 and $55.73 in the recent session.
Stock Snapshot
Stock Price History Chart
Contact Details
About Company
Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regulates metabolism of lipids, carbohydrates, and proteins throughout the body. It also conducts a Phase 2a clinical trial, the BALANCED study, to evaluate EFX in the treatment of biopsy-confirmed NASH patients. The company was formerly known as Pippin Pharmaceuticals, Inc. and changed its name to Akero Therapeutics, Inc. in May 2018. Akero Therapeutics, Inc. was incorporated in 2017 and is headquartered in South San Francisco, California.
Company Information
| Employees | 60 |
| Beta | -0.26 |
| Sales or Revenue | $0.00 |
| 5Y Sales Change% | 0% |
| Fiscal Year Ends | December |
| Sector | Healthcare |
| Industry | Biotechnology |
Frequently Asked Questions
Akero Therapeutics, Inc. (NASDAQ: AKRO) stock price is $54.00 in the last trading session. During the trading session, AKRO stock reached the peak price of $55.73 while $51.79 was the lowest point it dropped to. The percentage change in AKRO stock occurred in the recent session was 4.92% while the dollar amount for the price change in AKRO stock was $2.53.
The NASDAQ listed AKRO is part of Biotechnology industry that operates in the broader Healthcare sector. Akero Therapeutics, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.
Dr. Timothy Rolph
Co-Founder & Chief Scientific Officer
Mr. John J. Schembri
Vice President of Fin. & Controller
Ms. Catriona Yale
Executive Vice President & Chief Devel. Officer
Dr. Andrew Cheng M.D., Ph.D.
Pres, Chief Executive Officer & Director
Mr. Patrick Lamy
Senior Vice President of Commercial Strategy
Mr. William R. White J.D.
Executive Vice President, Chief Financial Officer, Treasurer & Head of Corporation Devel.
Dr. Jonathan M. Young J.D., Ph.D.
Co-Founder, Executive Vice President, Chief Operating Officer & Sec.
AKRO's closing price is 252.48% higher than its 52-week low of $15.32 where as its distance from 52-week high of $58.40 is -7.53%.
Number of AKRO employees currently stands at 60.
Official Website of AKRO is: https://www.akerotx.com
AKRO could be contacted at phone 650 487 6488 and can also be accessed through its website. AKRO operates from 601 Gateway Boulevard, South San Francisco, CA 94080, United States.
AKRO stock volume for the day was 3.61M shares. The average number of AKRO shares traded daily for last 3 months was 1.05M.
The market value of AKRO currently stands at $3.77B with its latest stock price at $54.00 and 69.8M of its shares outstanding.
Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.
© 2025 Stocks Telegraph All rights reserved.
Most stock quote data provided by financialmodelingprep.com